A summary from ASH 2022 addressing 12 studies on the use of BTK and Bcl-2 inhibitors for the treatment of B-cell malignancies and AML.
Slide-Kit
Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with a corticosteroid for relapsed/refractory (R/R) multiple myeloma (MM) patients harboring the t(11;14) translocation.
Reading
Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.
Reading
Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin’s lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM).
Reading
Poster presented at ASH 2022 describing the potential for Bcl-2 inhibition in adult patients with mature B-cell malignancies.
Reading
